
|Articles|March 1, 2004
Illuminating therapies
Washington, D.C. - Ongoing work regarding aminolevulinic acid (ALA) for photodynamic therapy provides a shining example of the value of off-label uses. The drug has earned UK approval for treating skin cancer and FDA approval for actinic keratoses. However, its most effective applications may well be cosmetic treatments including photo-rejuvenation, acne, and sebaceous gland hyperplasia.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














